By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

Education

Our Voices Blog

Clinical Trials in Canada: What’s currently being offered in breast cancer? - Early Stage

Title of Study: A randomised, double-blind, parallel group, placebo-controlled Phase 3 study to assess the efficacy and safety of OLAPARIB versus PLACEBO as adjuvant treatment in patients with germline BRCA 1/2 mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Patient Population: Germline BRCA 1/2 mutations and high risk HER2- primary breast cancer

Locations: Edmonton, Vancouver, Winnipeg, Hamilton, Toronto, Québec, Montreal, Greenfield Park

Click HERE for more information.


Title of Study: A Phase 3 randomized study to investigate the efficacy and safety of ATEZOLIZUMAB in combination with neoadjuvant ANTHRACYCLINE/NAB-PACLITAXEL-based chemotherapy compared with PLACEBO and chemotherapy in patients with primary invasive triple negative breast cancer

Patient Population: triple negative primary breast cancer

Locations: Oshawa, Québec, Montreal

Click HERE for more information.


Title of Study: PALbociclib CoLlaborative Adjuvant Study: A randomized Phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) – negative early breast cancer

Patient Population: Pre and postmenopausal women or men with stage II or stage III early invasive breast cancer that’s ER+ and/or PR+ and HER2-.

Locations: Abbotsford, Kelowna, Vancouver, Winnipeg, Saint John, Halifax, Kitchener, Hamilton, Toronto (PMH & Sunnybrook), Quebec, St. Catharines, Sherbrooke, Montreal (CHUM, Jewish General Hospital, MUHC Glen site), Saskatoon

Click HERE for more information

Photo by rawpixel.com on Unsplash

Related posts